{"id":104437,"date":"2025-05-26T17:23:48","date_gmt":"2025-05-26T15:23:48","guid":{"rendered":"https:\/\/www.pcb.ub.edu\/nuage-therapeutics-receives-e1-8-million-to-advance-the-development-of-its-first-oncology-therapy-targeting-intrinsically-disordered-proteins\/"},"modified":"2025-05-27T12:55:35","modified_gmt":"2025-05-27T10:55:35","slug":"nuage-therapeutics-receives-e1-8-million-to-advance-the-development-of-its-first-oncology-therapy-targeting-intrinsically-disordered-proteins","status":"publish","type":"post","link":"https:\/\/www.pcb.ub.edu\/en\/nuage-therapeutics-receives-e1-8-million-to-advance-the-development-of-its-first-oncology-therapy-targeting-intrinsically-disordered-proteins\/","title":{"rendered":"Nuage Therapeutics receives \u20ac1.8 million to advance the development of its first oncology therapy targeting intrinsically disordered proteins"},"content":{"rendered":"

Nuage Therapeutics<\/a>, a spinoff of the Institute for Biomedical Research (IRB Barcelona<\/a>) headquartered at the Barcelona Science Park, has secured a capital injection of \u20ac1.8 million from CDTI Innovaci\u00f3n through its Innvierte program, with participation from the international fund Sofinnova Capital X. This financial contribution will enable the Catalan biotech company to advance the development of new drugs targeting therapeutic targets traditionally considered intractable, such as intrinsically disordered proteins (IDPs), which are associated with severe diseases like cancer and have so far remained beyond the reach of conventional treatments.<\/strong><\/p>\n

The company has developed its own innovative technological platform capable of reconstituting these IDPs\u2014which do not adopt defined three-dimensional structures\u2014into structured secondary forms, opening a new avenue for the design of therapeutic molecules capable of interacting with them. This breakthrough represents a paradigm shift in drug discovery, as IDPs have historically been dismissed as viable targets due to their flexible nature and the difficulty of modulating their function with small-molecule compounds.<\/p>\n

Currently led by Stuart Hughes<\/strong>, the company focuses its efforts on converting this technology into real therapeutic solutions for patients with unmet medical needs. With this new financing round, Nuage Therapeutics aims to accelerate the preclinical development of its first oncology drug candidate and progress toward regulatory and clinical phases.<\/p>\n

Sofinnova Partners, the firm managing the Sofinnova Capital X fund, is one of Europe\u2019s leading venture capital firms specialized in life sciences. With offices in Paris, London, and Milan, it boasts an international team of professionals with solid scientific, medical, and business experience dedicated to supporting projects with high innovation potential and global health impact.<\/p>\n

CDTI Innovaci\u00f3n\u2019s support is part of its Innvierte initiative, a program aimed at fostering business innovation by co-financing technological projects in collaboration with private investors. This activity is channeled through Innvierte Econom\u00eda Sostenible SICC S.M.E., S.A., a self-managed venture capital company supervised by the CNMV, of which CDTI is the sole shareholder.<\/p>\n

This operation adds to previous investments in Nuage Therapeutics, including that of Asabys Partners, with an accumulated commitment from CDTI Innovaci\u00f3n of nearly \u20ac3 million. With continued support from strategic partners, Nuage consolidates its position as one of the most innovative biomedical startups in the Catalan and Spanish ecosystem, offering a unique technological proposition aimed at tackling highly complex therapeutic challenges.<\/p>\n

\u00bb More information:<\/strong> CDTI Innovaci\u00f3n website [+]<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Nuage Therapeutics, a spinoff of the Institute for Biomedical Research (IRB Barcelona) headquartered at the Barcelona Science Park, has secured a capital injection of \u20ac1.8 million from CDTI Innovaci\u00f3n through…<\/p>\n","protected":false},"author":1,"featured_media":104432,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[35],"tags":[294],"class_list":["post-104437","post","type-post","status-publish","format-standard","has-post-thumbnail","category-business","tag-nuage-therapeutics-en"],"acf":[],"yoast_head":"\nNuage Therapeutics receives \u20ac1.8 million to advance the development of its first oncology therapy targeting intrinsically disordered proteins - Parc Cient\u00edfic de Barcelona<\/title>\n<meta name=\"description\" content=\"This funding will enable progress in the development of new drugs targeting therapeutic sites considered intractable.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pcb.ub.edu\/en\/nuage-therapeutics-receives-e1-8-million-to-advance-the-development-of-its-first-oncology-therapy-targeting-intrinsically-disordered-proteins\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nuage Therapeutics receives \u20ac1.8 million to advance the development of its first oncology therapy targeting intrinsically disordered proteins - Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"og:description\" content=\"This funding will enable progress in the development of new drugs targeting therapeutic sites considered intractable.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pcb.ub.edu\/en\/nuage-therapeutics-receives-e1-8-million-to-advance-the-development-of-its-first-oncology-therapy-targeting-intrinsically-disordered-proteins\/\" \/>\n<meta property=\"og:site_name\" content=\"Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-26T15:23:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-27T10:55:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2025\/05\/Adobe-Express-file-10.png\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"330\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"adminpcb\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"adminpcb\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/nuage-therapeutics-receives-e1-8-million-to-advance-the-development-of-its-first-oncology-therapy-targeting-intrinsically-disordered-proteins\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/nuage-therapeutics-receives-e1-8-million-to-advance-the-development-of-its-first-oncology-therapy-targeting-intrinsically-disordered-proteins\\\/\"},\"author\":{\"name\":\"adminpcb\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\"},\"headline\":\"Nuage Therapeutics receives \u20ac1.8 million to advance the development of its first oncology therapy targeting intrinsically disordered proteins\",\"datePublished\":\"2025-05-26T15:23:48+00:00\",\"dateModified\":\"2025-05-27T10:55:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/nuage-therapeutics-receives-e1-8-million-to-advance-the-development-of-its-first-oncology-therapy-targeting-intrinsically-disordered-proteins\\\/\"},\"wordCount\":410,\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/nuage-therapeutics-receives-e1-8-million-to-advance-the-development-of-its-first-oncology-therapy-targeting-intrinsically-disordered-proteins\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/Adobe-Express-file-10.png\",\"keywords\":[\"Nuage Therapeutics\"],\"articleSection\":[\"COMPANIES\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/nuage-therapeutics-receives-e1-8-million-to-advance-the-development-of-its-first-oncology-therapy-targeting-intrinsically-disordered-proteins\\\/\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/nuage-therapeutics-receives-e1-8-million-to-advance-the-development-of-its-first-oncology-therapy-targeting-intrinsically-disordered-proteins\\\/\",\"name\":\"Nuage Therapeutics receives \u20ac1.8 million to advance the development of its first oncology therapy targeting intrinsically disordered proteins - Parc Cient\u00edfic de Barcelona\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/nuage-therapeutics-receives-e1-8-million-to-advance-the-development-of-its-first-oncology-therapy-targeting-intrinsically-disordered-proteins\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/nuage-therapeutics-receives-e1-8-million-to-advance-the-development-of-its-first-oncology-therapy-targeting-intrinsically-disordered-proteins\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/Adobe-Express-file-10.png\",\"datePublished\":\"2025-05-26T15:23:48+00:00\",\"dateModified\":\"2025-05-27T10:55:35+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\"},\"description\":\"This funding will enable progress in the development of new drugs targeting therapeutic sites considered intractable.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/nuage-therapeutics-receives-e1-8-million-to-advance-the-development-of-its-first-oncology-therapy-targeting-intrinsically-disordered-proteins\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/nuage-therapeutics-receives-e1-8-million-to-advance-the-development-of-its-first-oncology-therapy-targeting-intrinsically-disordered-proteins\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/nuage-therapeutics-receives-e1-8-million-to-advance-the-development-of-its-first-oncology-therapy-targeting-intrinsically-disordered-proteins\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/Adobe-Express-file-10.png\",\"contentUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/Adobe-Express-file-10.png\",\"width\":900,\"height\":330},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/nuage-therapeutics-receives-e1-8-million-to-advance-the-development-of-its-first-oncology-therapy-targeting-intrinsically-disordered-proteins\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nuage Therapeutics receives \u20ac1.8 million to advance the development of its first oncology therapy targeting intrinsically disordered proteins\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\",\"name\":\"Parc Cient\u00edfic de Barcelona\",\"description\":\"Universitat de Barcelona\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\",\"name\":\"adminpcb\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"caption\":\"adminpcb\"},\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/author\\\/adminpcb\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nuage Therapeutics receives \u20ac1.8 million to advance the development of its first oncology therapy targeting intrinsically disordered proteins - Parc Cient\u00edfic de Barcelona","description":"This funding will enable progress in the development of new drugs targeting therapeutic sites considered intractable.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pcb.ub.edu\/en\/nuage-therapeutics-receives-e1-8-million-to-advance-the-development-of-its-first-oncology-therapy-targeting-intrinsically-disordered-proteins\/","og_locale":"en_US","og_type":"article","og_title":"Nuage Therapeutics receives \u20ac1.8 million to advance the development of its first oncology therapy targeting intrinsically disordered proteins - Parc Cient\u00edfic de Barcelona","og_description":"This funding will enable progress in the development of new drugs targeting therapeutic sites considered intractable.","og_url":"https:\/\/www.pcb.ub.edu\/en\/nuage-therapeutics-receives-e1-8-million-to-advance-the-development-of-its-first-oncology-therapy-targeting-intrinsically-disordered-proteins\/","og_site_name":"Parc Cient\u00edfic de Barcelona","article_published_time":"2025-05-26T15:23:48+00:00","article_modified_time":"2025-05-27T10:55:35+00:00","og_image":[{"width":900,"height":330,"url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2025\/05\/Adobe-Express-file-10.png","type":"image\/png"}],"author":"adminpcb","twitter_card":"summary_large_image","twitter_misc":{"Written by":"adminpcb","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pcb.ub.edu\/en\/nuage-therapeutics-receives-e1-8-million-to-advance-the-development-of-its-first-oncology-therapy-targeting-intrinsically-disordered-proteins\/#article","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/en\/nuage-therapeutics-receives-e1-8-million-to-advance-the-development-of-its-first-oncology-therapy-targeting-intrinsically-disordered-proteins\/"},"author":{"name":"adminpcb","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021"},"headline":"Nuage Therapeutics receives \u20ac1.8 million to advance the development of its first oncology therapy targeting intrinsically disordered proteins","datePublished":"2025-05-26T15:23:48+00:00","dateModified":"2025-05-27T10:55:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/en\/nuage-therapeutics-receives-e1-8-million-to-advance-the-development-of-its-first-oncology-therapy-targeting-intrinsically-disordered-proteins\/"},"wordCount":410,"image":{"@id":"https:\/\/www.pcb.ub.edu\/en\/nuage-therapeutics-receives-e1-8-million-to-advance-the-development-of-its-first-oncology-therapy-targeting-intrinsically-disordered-proteins\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2025\/05\/Adobe-Express-file-10.png","keywords":["Nuage Therapeutics"],"articleSection":["COMPANIES"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.pcb.ub.edu\/en\/nuage-therapeutics-receives-e1-8-million-to-advance-the-development-of-its-first-oncology-therapy-targeting-intrinsically-disordered-proteins\/","url":"https:\/\/www.pcb.ub.edu\/en\/nuage-therapeutics-receives-e1-8-million-to-advance-the-development-of-its-first-oncology-therapy-targeting-intrinsically-disordered-proteins\/","name":"Nuage Therapeutics receives \u20ac1.8 million to advance the development of its first oncology therapy targeting intrinsically disordered proteins - Parc Cient\u00edfic de Barcelona","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/en\/nuage-therapeutics-receives-e1-8-million-to-advance-the-development-of-its-first-oncology-therapy-targeting-intrinsically-disordered-proteins\/#primaryimage"},"image":{"@id":"https:\/\/www.pcb.ub.edu\/en\/nuage-therapeutics-receives-e1-8-million-to-advance-the-development-of-its-first-oncology-therapy-targeting-intrinsically-disordered-proteins\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2025\/05\/Adobe-Express-file-10.png","datePublished":"2025-05-26T15:23:48+00:00","dateModified":"2025-05-27T10:55:35+00:00","author":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021"},"description":"This funding will enable progress in the development of new drugs targeting therapeutic sites considered intractable.","breadcrumb":{"@id":"https:\/\/www.pcb.ub.edu\/en\/nuage-therapeutics-receives-e1-8-million-to-advance-the-development-of-its-first-oncology-therapy-targeting-intrinsically-disordered-proteins\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pcb.ub.edu\/en\/nuage-therapeutics-receives-e1-8-million-to-advance-the-development-of-its-first-oncology-therapy-targeting-intrinsically-disordered-proteins\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.pcb.ub.edu\/en\/nuage-therapeutics-receives-e1-8-million-to-advance-the-development-of-its-first-oncology-therapy-targeting-intrinsically-disordered-proteins\/#primaryimage","url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2025\/05\/Adobe-Express-file-10.png","contentUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2025\/05\/Adobe-Express-file-10.png","width":900,"height":330},{"@type":"BreadcrumbList","@id":"https:\/\/www.pcb.ub.edu\/en\/nuage-therapeutics-receives-e1-8-million-to-advance-the-development-of-its-first-oncology-therapy-targeting-intrinsically-disordered-proteins\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pcb.ub.edu\/en\/"},{"@type":"ListItem","position":2,"name":"Nuage Therapeutics receives \u20ac1.8 million to advance the development of its first oncology therapy targeting intrinsically disordered proteins"}]},{"@type":"WebSite","@id":"https:\/\/www.pcb.ub.edu\/es\/#website","url":"https:\/\/www.pcb.ub.edu\/es\/","name":"Parc Cient\u00edfic de Barcelona","description":"Universitat de Barcelona","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pcb.ub.edu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021","name":"adminpcb","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","caption":"adminpcb"},"url":"https:\/\/www.pcb.ub.edu\/en\/author\/adminpcb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/104437","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/comments?post=104437"}],"version-history":[{"count":1,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/104437\/revisions"}],"predecessor-version":[{"id":104440,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/104437\/revisions\/104440"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media\/104432"}],"wp:attachment":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media?parent=104437"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/categories?post=104437"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/tags?post=104437"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}